Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
Small molecule therapy is a critical component of targeted anticancer treatment, with
tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic …
tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic …
[HTML][HTML] Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring
L Chen, Y Zhang, YX Zhang, WL Wang, DM Sun… - Journal of …, 2023 - Elsevier
Tyrosine kinase inhibitors (TKIs) have emerged as the first-line small molecule drugs in
many cancer therapies, exerting their effects by impeding aberrant cell growth and …
many cancer therapies, exerting their effects by impeding aberrant cell growth and …
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation
S He, Q Shao, J Zhao, J Bian, Y Zhao, X Hao… - Cancer Chemotherapy …, 2023 - Springer
Background Imatinib is presently the first-line choice for the treatment of chronic myeloid
leukemia. However, there are limited real-world data on Chinese patients to support …
leukemia. However, there are limited real-world data on Chinese patients to support …
External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia
Á Corral Alaejos, A Zarzuelo Castañeda… - British Journal of …, 2022 - Wiley Online Library
Aims Imatinib is considered the standard first‐line treatment in newly diagnosed patients
with chronic‐phase myeloid leukaemia (CML). Several imatinib population pharmacokinetic …
with chronic‐phase myeloid leukaemia (CML). Several imatinib population pharmacokinetic …
Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens
J Adiwidjaja, AS Gross, AV Boddy… - British Journal of …, 2022 - Wiley Online Library
Aims This study implements a physiologically‐based pharmacokinetic (PBPK) modelling
approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing …
approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing …
Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia
B Shriyan, P Mehta, A Patil, S Jadhav, S Kumar… - European Journal of …, 2022 - Springer
Purpose Imatinib is a substrate of CYP3A4, ABCB1 and ABCG2, and is known to have wide
variability in pharmacokinetics (PK). At the same time, a clear relationship between drug …
variability in pharmacokinetics (PK). At the same time, a clear relationship between drug …
Determination of Tyrosine Kinase Inhibitors via Capillary Electrophoresis with Tandem Mass Spectrometry and Online Stacking Preconcentration
J Petr - Pharmaceuticals, 2023 - mdpi.com
Capillary electrophoresis connected with tandem mass spectrometry was employed for the
development of a method for determination of various tyrosine kinase inhibitors in plasma …
development of a method for determination of various tyrosine kinase inhibitors in plasma …
[HTML][HTML] Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients
JSD Batcha, V Gota, S Matcha, AP Raju… - Cancer …, 2024 - pmc.ncbi.nlm.nih.gov
Methods A systematic review was conducted through PubMed, and WoS databases to
identify PopPK models. Clinical data collected in adult CML patients treated with imatinib …
identify PopPK models. Clinical data collected in adult CML patients treated with imatinib …
Chronic myeloid leukemia and pregnancy: when dreams meet reality. State of the art, management and outcome of 41 cases, nilotinib placental transfer
E Abruzzese, S Aureli, F Bondanini… - Journal of Clinical …, 2022 - mdpi.com
The overwhelming success of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid
leukemia (CML) patients has opened a discussion among medical practitioners and the lay …
leukemia (CML) patients has opened a discussion among medical practitioners and the lay …
Enhanced efficacy, cellular uptake, and antiangiogenic activity of the optimized imatinib mesylate-loaded proniosomal-derived nanovesicles
AR Gardouh, TM Ewedah, FI Abd-Allah… - Journal of Drug Delivery …, 2021 - Elsevier
This study was premeditated to elaborate an optimized imatinib mesylate (IM)–loaded
proniosomal–derived nanovesicles to investigate its influence on IM effectiveness, cellular …
proniosomal–derived nanovesicles to investigate its influence on IM effectiveness, cellular …